Thomas Leggett - 15 Mar 2026 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
Chief Financial Officer
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Issuer symbol
STOK
Transactions as of
15 Mar 2026
Net transactions value
$0
Form type
4
Filing time
17 Mar 2026, 17:26:02 UTC
Previous filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Leggett Thomas Chief Financial Officer C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD /s/ Jonathan Allan, Attorney-in-Fact 17 Mar 2026 0001774690

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise +14,750 $0.000000* 14,750 15 Mar 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Restricted Stock Units Options Exercise -14,750 -25% $0.000000* 44,250 15 Mar 2026 Common Stock 14,750 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F2 The award vested or vests as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.